Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Understanding Barriers Impacting upon Patient Wellbeing: A Nationwide Italian Survey and Expert Opinion of Dermatologists Treating Patients with Moderate-to-Severe Psoriasis.
Prignano F, Argenziano G, Bardazzi F, Borroni RG, Brunasso AMG, Burlando M, Cagni AE, Campione E, Cinotti E, Colonna F, Cuccia A, Dastoli S, De Pasquale R, De Simone C, Di Lernia V, Dini V, Fabbrocini G, Galluzzi C, Giacchetti A, Giofrè C, Lasagni C, Lembo S, Loconsole F, Montesu MA, Pella P, Piaserico S, Pigatto P, Richetta AG, Scuotto A, Stroppiana E, Venturini M, Vinci AS, Zichichi L, Fargnoli MC. Prignano F, et al. Among authors: dastoli s. J Clin Med. 2023 Dec 24;13(1):101. doi: 10.3390/jcm13010101. J Clin Med. 2023. PMID: 38202108 Free PMC article.
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy.
Talamonti M, Galluzzo M, Chiricozzi A, Quaglino P, Fabbrocini G, Gisondi P, Marzano AV, Potenza C, Conti A, Parodi A, Belloni Fortina A, Bardazzi F, Argenziano G, Rongioletti F, Stingeni L, Micali G, Loconsole F, Venturini M, Bongiorno MR, Feliciani C, Rubegni P, Amerio P, Fargnoli MC, Pigatto P, Savoia P, Nisticò SP, Giustini S, Carugno A, Cannavò SP, Rech G, Prignano F, Offidani A, Lombardo M, Zalaudek I, Bianchi L, Peris K; PSO-BIO-COVID study group. Talamonti M, et al. J Eur Acad Dermatol Venereol. 2020 Dec;34(12):e770-e772. doi: 10.1111/jdv.16841. Epub 2020 Aug 10. J Eur Acad Dermatol Venereol. 2020. PMID: 32735716 Free PMC article. No abstract available.
Investigating psoriasis awareness among patients in Italy: validation of a questionnaire.
Bardazzi F, Amerio P, Amoruso G, Campanati A, Conti A, De Simone C, Gisondi P, Gualdi G, Guarneri C, Loconsole F, Mazzotta A, Musumeci ML, Odorici G, Piaserico S, Potenza C, Scudeller L; Alphard Study Group. Bardazzi F, et al. Eur Rev Med Pharmacol Sci. 2014 Nov;18(22):3435-52. Eur Rev Med Pharmacol Sci. 2014. PMID: 25491619 Free article.
Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.
Neri L, Peris K, Longo C, Calvieri S, Frascione P, Parodi A, Eibenschuz L, Bottoni U, Pellacani G; Actinic Keratosis - TReatment Adherence INitiative (AK-TRAIN) study group. Neri L, et al. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):93-107. doi: 10.1111/jdv.15142. Epub 2018 Jul 8. J Eur Acad Dermatol Venereol. 2019. PMID: 29920789
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study.
Russo F, Galluzzo M, Stingeni L, Persechino S, Zichichi L, Conti A, Giofrè C, Dini V, Vispi M, Atzori L, Cattaneo A, Parodi A, Bardazzi F, Stinco G, Dapavo P, Girolomoni G, Musumeci ML, Papini M, Venturini M, Dastoli S, Di Nuzzo S, Fargnoli MC, Pagnanelli G, Bernardini N, Gambini DM, Malagoli P, Mazzatenta C, Peris K, Zalaudek I, Fabbrocini G, Loconsole F, Vassallo C, Pietroleonardo L, Prignano F, Franchi C, Offidani AM, Bonifati C, Di Lernia V, Gigante G, Bartezaghi MS, Franchi M, Ursoleo P, Aloisi E. Russo F, et al. Among authors: dastoli s. Clin Cosmet Investig Dermatol. 2023 Dec 12;16:3561-3574. doi: 10.2147/CCID.S416149. eCollection 2023. Clin Cosmet Investig Dermatol. 2023. PMID: 38107670 Free PMC article.
Safety of omalizumab in chronic urticaria during pregnancy: a real-life study.
Patruno C, Guarneri F, Nettis E, Bonzano L, Filippi F, Ribero S, Foti C, Rubegni P, Balato A, Miniello A, Motolese A, Piraccini BM, Quaglino P, Romita P, Lazzeri L, Buononato D, Dastoli S, Raia F, Napolitano M. Patruno C, et al. Among authors: dastoli s. Clin Exp Dermatol. 2024 Mar 21;49(4):344-347. doi: 10.1093/ced/llad386. Clin Exp Dermatol. 2024. PMID: 37956096
Correction to: AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History.
Stingeni L, Chiricozzi A, Calzavara-Pinton P, Napolitano M, Peris K, Schena D, Patruno C, Rossi M, Foti C, Fargnoli MC, Corazza M, Ferrucci SM, Pigatto PD, Romanelli M, Fabbrocini G, Girolomoni G, Passante M, Romita P, Esposito M, Schettini N, Marzano AV, Tonini G, Marietti R, Casciola G, Argenziano G, Hansel K; AtopyReg® study group. Stingeni L, et al. Am J Clin Dermatol. 2024 Jan;25(1):161. doi: 10.1007/s40257-023-00822-3. Am J Clin Dermatol. 2024. PMID: 37934365 Free PMC article. No abstract available.
AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History.
Stingeni L, Chiricozzi A, Calzavara-Pinton P, Napolitano M, Peris K, Schena D, Patruno C, Rossi M, Foti C, Fargnoli MC, Corazza M, Ferrucci SM, Pigatto PD, Romanelli M, Fabbrocini G, Girolomoni G, Passante M, Romita P, Esposito M, Schettini N, Marzano AV, Tonini G, Marietti R, Casciola G, Argenziano G, Hansel K; AtopyReg® study group. Stingeni L, et al. Am J Clin Dermatol. 2024 Jan;25(1):149-160. doi: 10.1007/s40257-023-00819-y. Epub 2023 Sep 19. Am J Clin Dermatol. 2024. PMID: 37725229 Free PMC article.
Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy.
Dastoli S, Passante M, Loconsole F, Mortato E, Balato A, Piccolo V, Guarneri C, Macca L, Provenzano E, Valenti G, D'Amico D, Micali G, Musumeci ML, Palazzo G, Foti C, Romita P, Fabbrocini G, Megna M, Sammarra I, Bennardo L, Patruno C. Dastoli S, et al. J Dermatolog Treat. 2023 Dec;34(1):2200868. doi: 10.1080/09546634.2023.2200868. J Dermatolog Treat. 2023. PMID: 37026590 Free article.
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
Stingeni L, Bianchi L, Antonelli E, Caroppo ES, Ferrucci SM, Gurioli C, Ortoncelli M, Fabbrocini G, Nettis E, Schena D, Napolitano M, Gola M, Bonzano L, Rossi M, Belloni Fortina A, Balato A, Peris K, Foti C, Guarneri F, Romanelli M, Patruno C, Savoia P, Esposito M, Russo F, Errichetti E, Bianchelli T, Bianchi L, Pellacani G, Feliciani C, Offidani A, Corazza M, Micali G, Milanesi N, Malara G, Chiricozzi A, Tramontana M, Hansel K; DADA - Dupilumab for Atopic Dermatitis of the Adolescence study group. Stingeni L, et al. J Eur Acad Dermatol Venereol. 2023 Mar;37(3):e384-e388. doi: 10.1111/jdv.18648. Epub 2022 Oct 18. J Eur Acad Dermatol Venereol. 2023. PMID: 36225088 No abstract available.
55 results